Replagal Articles
EMA approves Shire Vpriv plant in USA
23 February 2012
Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv
1 September 2011
FDA advisory panel backs approval of Shire’s Firazyr for HAE; Replagal site cleared by EMA
27 June 2011
Showing 1-6 of 6 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
